Ovarian hyperstimulation syndrome (OHSS) is a complication that occurs as a result of assisted reproductive technology (ART) techniques such as ovulation induction and in vitro fertilization (IVF). It is characterized by enlargement of the ovaries, accumulation of fluid in the abdominal cavity, and other systemic manifestations. The disease is associated with increased secretion of hormones, which leads to changes in vascular permeability and tissue edema. Symptoms of OHSS can range from a mild degree that resolves without serious intervention to a severe form that requires medical supervision and active treatment. The main clinical manifestations include lower abdominal pain, dyspeptic symptoms, abdominal enlargement, and progressive general weakness.
History of the disease and interesting historical facts
Ovarian hyperstimulation syndrome was first described by researchers in 1956, when the active development of reproductive medicine methods began. The advent of ART in the 1970s contributed to an increase in the incidence of OHSS, which made it a pressing problem in obstetrics and gynecology. In the 1980s, after accumulating clinical experience, recommendations were proposed for the prevention and diagnosis of this syndrome. An interesting fact is that in the 1990s, the first attempts to develop preventive protocols based on an individual approach to patients appeared, which significantly improved treatment outcomes.
Epidemiology
According to recent studies, the incidence of ovarian hyperstimulation syndrome varies from 3% to 20% among women undergoing ART treatment. In patients undergoing gonadotropin therapy for ovulation induction, the incidence can reach 30%. It is important to note that the severity of OHSS varies, and in most cases the disease is mild to moderate, but about 1-2% cases worsen to severe.
Genetic predisposition to this disease
Research suggests that genetic predisposition may play a role in the development of ovarian hyperstimulation syndrome. In particular, some markers have been identified, such as polymorphisms in genes responsible for hormonal metabolism, including the FSHR gene (follicle-stimulating hormone receptor) and the LHR gene (luteinizing hormone receptor). These changes may increase the sensitivity of the ovaries to exogenous gonadotropins, which in turn increases the risk of hyperstimulation.
Risk factors for the development of this disease
There are several factors that can increase your risk of developing ovarian hyperstimulation syndrome, including:
- Age: Younger women, especially those under 35 years of age, have a higher risk of developing OHSS.
- Prior hyperstimulation: A history of hyperstimulation episodes may increase the likelihood of recurrence.
- Polycystic ovary syndrome: Women with polycystic ovary syndrome have increased sensitivity to gonadotropins.
- High estrogen levels: High hormone levels can put you at significant risk for developing OHSS.
- Incorrect drug dosages: Increasing the dose of gonadotropins without careful monitoring can lead to hyperstimulation.
Diagnosis of this disease
Diagnosis of ovarian hyperstimulation syndrome is based on clinical symptoms and imaging studies. The main symptoms of OHSS include:
- Pain and discomfort in the abdominal area.
- Abdominal enlargement.
- Nausea and vomiting.
- Shortness of breath and a feeling of fullness in the abdomen.
Laboratory tests can help determine hormone levels and identify possible electrolyte imbalances. Radiological tests, such as pelvic ultrasound, can visualize the ovaries and assess their size and condition. Differential diagnosis includes ruling out other conditions, such as acute abdomen, hernia, or ascites.
Treatment
Treatment for ovarian hyperstimulation syndrome depends on its severity. In mild cases, outpatient observation and symptomatic therapy may be possible, including:
- Supportive therapy: hydration, correction of electrolyte disturbances.
- Pain relief: use of non-steroidal anti-inflammatory drugs.
More severe cases may require hospitalization, intravenous fluids, and hormonal agents to control hormone levels. Rarely, if there is large volumes of fluid in the abdomen, laparocentesis may be needed to remove the fluid.
List of medications used to treat this disease
Among the drugs used to treat OHSS, the following can be distinguished:
- Furosemide: to correct hypervolemia.
- Analgesics: to relieve pain.
- Hormonal drugs: to normalize hormone levels.
Disease monitoring
Monitoring of women with ovarian hyperstimulation syndrome includes regular examinations and tests. The prognosis depends on the severity of the disease. In most cases, with proper monitoring, the prognosis is good. Possible complications include thrombosis, development of ascites, and deterioration of kidney function.
Age-related features of the disease
Ovarian hyperstimulation syndrome may manifest itself differently in different age groups. Young women often have mild to moderate OHSS, while older patients may have a more severe form of the disease due to the presence of concomitant diseases and decreased resistance.
Questions and Answers
- What are the main symptoms of ovarian hyperstimulation syndrome? The main symptoms include abdominal pain, abdominal distension, nausea and vomiting.
- How is ovarian hyperstimulation syndrome diagnosed? Diagnosis is made on the basis of the clinical picture, laboratory tests and ultrasound of the pelvic organs.
- Is it possible to avoid developing ovarian hyperstimulation syndrome? Yes, the risk can be reduced by carefully selecting the doses of gonadotropins and carefully monitoring the patient’s condition.
- How is ovarian hyperstimulation syndrome treated? Treatment may range from observation and supportive care to hospitalization and the use of specialized medications.
- What is the prognosis for ovarian hyperstimulation syndrome? The prognosis for mild to moderate forms of the disease is generally favorable, but severe cases require intensive care.
